Severe muscle weakness during treatment with pegylated interferon alfa for chronic hepatitis C virus infection A rare complication
author
Abstract:
Background: Interferons (IFNs) are common therapeutics for several diseases such as viral hepatitis, multiple sclerosis and malignancy. A variety of autoimmune related side effects have been observed during IFN therapy. Rare cases of myopathy, polymyositis or dermatomyositis have been reported during therapy with high doses of IFN^5. Case Presentation: In this report, we describe a case with severe muscle weakness but near normal muscles' enzymes during treatment of chronic hepatic C infection with pegylated IFN ^5 2a in a patient with major beta thalassemiaConclusion: This report suggests that severe weakness with normal muscles^5 enzymes may occur during IFN therapy.
similar resources
severe muscle weakness during treatment with pegylated interferon alfa for chronic hepatitis c virus infection a rare complication
background: interferons (ifns) are common therapeutics for several diseases such as viral hepatitis, multiple sclerosis and malignancy. a variety of autoimmune related side effects have been observed during ifn therapy. rare cases of myopathy, polymyositis or dermatomyositis have been reported during therapy with high doses of ifn^5. case presentation: in this report, we describe a case with se...
full textPegylated interferon-alfa plus ribavirin therapies for chronic hepatitis C.
Until HCV NS3/4A protease inhibitors become available at the end of 2011, the combination pegylated-interferon (PEG-IFN)-alfa and ribavirin (RBV) will remain the standard treatment for chronic hepatitis C patients. In some hepatitis C virus-infected patients, PEG-IFN plus RBV treatment against HCV should continue to be used because of side effects of new drugs such as anemia. Our Japanese exper...
full textSubcutaneous Sarcoidosis during Pegylated Interferon Alfa and Ribavirin Treatment for Chronic Hepatitis C
Interferon is used to treat hepatitis C virus infection and its cutaneous side effects are well known. Recently, interferon-induced sarcoidosis has been reported. We report a new case of sarcoidosis during pegylated interferon alfa and ribavirin treatment with an unusual presentation in a woman with previous episodes of erythema nodusum and nodular vasculitis related to HCV.
full textPegylated Interferon and Ribavirin Treatment for Hepatitis C Virus Infection
1Department of Gastroenterology, Tokai University School of Medicine, 143 Shimokasuya, Isehara 259-1193, Japan 2Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, Palo Alto, CA 94304-1509, USA 3Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung...
full textSafety and Efficacy of Pegylated Interferon Alfa-2a for the Treatment of Hepatitis C in Patients with Major Thalassemia
Background: Hepatitis C virus (HCV) infection is the most common transfusion transmitted disease in poly-transfused patients worldwide. In this study we aimed to evaluate the effects of pegylated interferon alfa-2a (PEG-IFN A-2a) in reducing serum ALT and eradicating serum hepatitis C virus (HCV) RNA in HCV infected polytransfused thalassemic patients. Materials and Methods: A cohort of 51 HCV-...
full textInterstitial Pneumonitis Related to Pegylated Interferon Alfa-2a Treatment in a Patient with Chronic Hepatitis C
Alkan E, Akin M, Adanir H, Tuna Y. Interstitial Pneumonitis Related to Pegylated Interferon Alfa-2a Treatment in a Patient with Chronic Hepatitis C. Euroasian J Hepato-Gastroenterol 2016;6(1):91-92.
full textMy Resources
Journal title
volume 1 issue None
pages 111- 114
publication date 2010-01
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023